The origin and phenotype of stem cells in human prostate cancer remains a subject of much conjecture.
In this scenario, CD133 has been successfully used as a stem cell marker in both normal prostate and prostate cancer. However, cancer stem cells have been identified without the use of this marker, opening up the possibility of a CD133 negative cancer stem cell. In this chapter, we review the current literature regarding prostate cancer stem cells, with specific reference to the expression of CD133 as a stem cell marker to identify and purify stem cells in normal prostate epithelium and prostate cancer.
Written by:
Pellacani D, Oldridge EE, Collins AT, Maitland NJ. Are you the author?
YCR Cancer Research Unit, Department of Biology, University of York, Wentworth Way, YO10 5DD, York, UK.
Reference: Adv Exp Med Biol. 2013;777:167-84.
doi: 10.1007/978-1-4614-5894-4_11
PubMed Abstract
PMID: 23161082
UroToday.com Investigative Urology Section
